methylene blue has been researched along with kynurenic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Büyükuysal, RL | 1 |
| Agrawal, N; Aron, R; Finkbeiner, S; Glabe, C; Lau, A; Lotz, GP; Marsh, JL; Muchowski, PJ; Necula, M; Sontag, EM; Thompson, LM; Tran, A; Yang, G | 1 |
2 other study(ies) available for methylene blue and kynurenic acid
| Article | Year |
|---|---|
Effect of nitric oxide donors on endogenous dopamine release from rat striatal slices. II: The role of voltage-dependent sodium channels, calcium channel activation, reverse transport mechanism, guanylate cyclase and endogenous glutamate.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Calcium Channel Blockers; Corpus Striatum; Dizocilpine Maleate; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Glutamic Acid; Guanylate Cyclase; Hydroxylamine; In Vitro Techniques; Kynurenic Acid; Male; Methylene Blue; Nitric Oxide; Nitroprusside; Nomifensine; omega-Conotoxin GVIA; Peptides; Rats; Rats, Sprague-Dawley; Sodium Channels; Tetrodotoxin; Vasodilator Agents; Verapamil | 1997 |
Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.
Topics: Analysis of Variance; Animals; Brain-Derived Neurotrophic Factor; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; Drosophila; Embryo, Mammalian; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Humans; Huntingtin Protein; Huntington Disease; Kynurenic Acid; Methylene Blue; Mice; Mice, Inbred C57BL; Microscopy, Atomic Force; Mutation; Nerve Tissue Proteins; Neurodegenerative Diseases; Neurons; Psychomotor Performance; Rats; Rotarod Performance Test; Transfection; Trinucleotide Repeat Expansion | 2012 |